Cancer and Surgery Clinical Group

This clinical group provides cancer services, specialist surgery and benign services such as renal, gastro-intestinal medicine and haematology.

We are one of the leading cancer centres in the country, with the purpose-built Cancer Centre at Guy’s providing comprehensive and personalised care. We continue to build a global reputation for surgery and perioperative care and strive to be a leader in research and innovation.

A world leader in caring for people with cancer

As a comprehensive cancer centre, with an embedded NHS England Genomics Laboratory Hub, we are able to combine research with care from early diagnosis throughout the whole patient pathway. Our Clinical Research Facility is a leading Phase 1 trial unit, offering our patients the widest range of treatment options.

Our aim is to be a leading European centre for radiotherapy, building on our strength in imaging. We will offer improved accuracy in radiotherapy by using artificial intelligence (AI) to auto-contour, and combining imaging modalities to drive better outcomes for patients.

As a multi-specialty centre, we will work with our cardiovascular colleagues to develop our services as a leading European centre for cardio-oncology. This combination of specialties enables us to meet all the clinical needs of our patients, underpinned by our holistic approach to caring for cancer patients and their families.

A national centre for specialist surgery

We are uniquely positioned with our range of specialist services to offer the newest techniques and technologies to our patients and to train the next generation of surgical and peri-operative teams.

We are the UK’s largest robotic surgery provider, offering multi-platform, multi-specialty robotics. Our vision is to be a European centre of excellence in robotics and at the forefront of digital technology and AI in surgery in the UK, building on the strength of our clinical teams and collaboration with the King’s College London Medtech hub.

Advanced cell and gene therapies

We are a leader in clinical trials for advanced cell and gene therapies and one of a small number of commissioned national sites for haemophilia gene therapy treatment. Our clinical expertise and multi-specialty campus enable us to offer these treatments for cancer and a range of benign conditions. Our ambition is to be a world leader in the delivery of these new treatments. We will do this as the first NHS- commissioned site for cellular therapies to treat cancer; a first wave provider of gene and vaccine therapy for cancer; and the UK’s first centre providing multi- specialty immune therapy infusions.

Research and innovation

Our strength in research and innovation is built on the diversity and scale of our patient populations, our data and our partnerships. We will harness clinical data within Epic and build on our close partnership with King’s College London to best utilise our comprehensive multi-modal research dataset, including biobanking and real-world evidence. We will strengthen our existing expertise in cancer, inflammatory bowel disease, haematology including sickle cell disease, and renal.

Infrastructure

Key projects we aim to deliver include: increasing theatre capacity at Guy’s Surgical Hub; endoscopy expansion to support local access and complex therapy; expanding apheresis capacity to support advanced therapy delivery; and investing in our robotic surgery programme to support our ambition as a centre of excellence.